What are the prescription, physical, alternative, herbal, and vitamin treatments for restless legs syndrome (RLS)?

Treatment Options for Restless Legs Syndrome

For adults with RLS, start with gabapentin enacarbil, gabapentin, or pregabalin as first-line pharmacologic therapy, and address iron deficiency with IV ferric carboxymaltose if ferritin ≤75 ng/mL or transferrin saturation <20%. 1

Initial Management: Address Exacerbating Factors First

Before prescribing medications, eliminate aggravating factors 1:

• Discontinue or switch: antihistamines, SSRIs/SNRIs, antipsychotics, metoclopramide
• Reduce or eliminate: alcohol and caffeine
• Treat: obstructive sleep apnea if present

Iron Assessment and Repletion (Critical First Step)

Check iron studies in all RLS patients - obtain fasting morning ferritin and transferrin saturation, avoiding iron supplements/foods for 24 hours prior 1.

Iron Supplementation Guidelines (Different from General Population):

Adults:

• Ferritin ≤75 ng/mL OR transferrin saturation <20%: Use oral or IV iron
• Ferritin 75-100 ng/mL: Use IV iron only
• Target ferritin >100 ng/mL

Children:

• Ferritin <50 ng/mL: Use oral or IV iron 1

Iron Formulations by Strength of Recommendation:

Strong recommendations:

• IV ferric carboxymaltose (preferred IV formulation) 1

Conditional recommendations:

• IV low molecular weight iron dextran 1
• IV ferumoxytol 1
• Oral ferrous sulfate with vitamin C 1

Important caveat: Ferric carboxymaltose carries higher risk of hypophosphatemia compared to other IV formulations 2.

First-Line Pharmacologic Therapy: Alpha-2-Delta Ligands

All three receive STRONG recommendations 1:

1. Gabapentin enacarbil (extended-release formulation)
2. Gabapentin
3. Pregabalin

These are now preferred over dopamine agonists for long-term management because they avoid augmentation risk 2, 3, 4.

Second-Line and Adjunctive Therapies

Conditional Recommendations (Weaker Evidence):

Medications:

• Dipyridamole 1
• Extended-release oxycodone and other opioids - for refractory cases 1
  • Recent registry data show reassuring safety profile 2

Physical/Device Therapy:

• Bilateral high-frequency peroneal nerve stimulation - can be used as adjunct in refractory RLS 1, 2

Dopamine Agonists: Now Discouraged for Routine Use

The 2025 AASM guidelines represent a major paradigm shift - dopamine agonists are now suggested AGAINST for standard use due to augmentation risk (paradoxical worsening of symptoms with long-term use) 1, 4:

• Pramipexole (conditional recommendation against)
• Ropinirole (conditional recommendation against)
• Transdermal rotigotine (conditional recommendation against)
• Levodopa (conditional recommendation against)
• Cabergoline (STRONG recommendation against) - cardiac valvulopathy risk 1

Exception: May consider short-term use in patients who prioritize immediate symptom relief over long-term augmentation risk 1.

Medications to AVOID

Conditional recommendations against:

• Bupropion 1
• Carbamazepine 1
• Clonazepam 1
• Valproic acid 1
• Valerian (herbal) 1

Special Populations

End-Stage Renal Disease (ESRD) with RLS:

Recommended:

• Gabapentin (conditional) 1
• IV iron sucrose if ferritin <200 ng/mL AND transferrin saturation <20% (conditional) 1
• Vitamin C (conditional) 1

Evidence from meta-analysis: Vitamin C and E both significantly improve hemodialysis-associated RLS, with vitamin C equivalent to 0.18 mg pramipexole 5.

Pregnancy:

Consider pregnancy-specific safety profiles for all treatments 1. Iron supplementation is particularly important as folate deficiency is associated with RLS in pregnant women 5.

Children:

Oral ferrous sulfate with appropriate iron parameters (ferritin <50 ng/mL) receives conditional recommendation 1.

Vitamins and Supplements

Evidence-Based Vitamin Therapy:

Vitamin C and E (for hemodialysis patients):

• Strong evidence for symptom improvement 1, 5
• Vitamin C + E combination effective 5

Vitamin B6:

• Significantly improved primary RLS in meta-analysis 5

Vitamin D:

• Lower levels found in both primary and secondary RLS patients 5
• Oral supplementation did NOT significantly improve RLS (P=0.05) 5
• Consider supplementation if deficient, but not RLS-specific treatment

Vitamin B12 and B1:

• No deficiency found in RLS patients 5
• Not recommended

Folate:

• Lower in pregnant RLS patients only 5
• Consider in pregnancy

Alternative and Physical Therapies

Moderate Evidence (from research studies):

Exercise training:

• Should be recommended for RLS symptom treatment 6
• Effective in both primary and uremic RLS 7

Pneumatic compression devices:

• Conditional recommendation from 2016 AAN guideline 8
• Improves symptoms and sleep 7

Preliminary Evidence (insufficient for strong recommendations):

• Yoga 6, 7
• Acupuncture 6, 7
• Near-infrared light therapy 6, 8
• Transcranial magnetic stimulation 8, 7
• Transcutaneous spinal direct current stimulation 7
• Vibrating pads (for subjective sleep improvement) 8

Chinese herbs: Insufficient evidence 6

Clinical Algorithm

1. Eliminate exacerbating factors (medications, substances, sleep apnea)
2. Check iron studies (fasting morning ferritin, transferrin saturation)
3. If iron deficient: Treat with IV ferric carboxymaltose (preferred) or oral ferrous sulfate + vitamin C
4. If iron adequate or as concurrent therapy: Start alpha-2-delta ligand (gabapentin enacarbil, gabapentin, or pregabalin)
5. If refractory: Consider opioids, peroneal nerve stimulation, or short-term dopamine agonist with close monitoring
6. Encourage regular exercise throughout treatment

Critical Pitfalls to Avoid

• Do NOT use dopamine agonists as first-line long-term therapy - the 2025 guidelines fundamentally changed this approach 4
• Do NOT use standard iron supplementation thresholds - RLS requires higher ferritin targets (>100 ng/mL) than general population 1
• Do NOT forget to check iron studies - even without anemia, iron deficiency is a core pathophysiological target 3
• Do NOT use cabergoline - strong recommendation against due to cardiac valve risks 1